Adial (ADIL). Don’t Give up Drinking. Just Drink Less!

Hmm, Now Here’s a Novel Idea and Every Heavy Drinkers Dream!

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

Experts agree that there are benefits to reductions in drinking, supporting the ongoing development of non-abstinence-based therapies to treat alcohol use disorder.

LIVE QUOTE


PRESS RELEASE

CHARLOTTESVILLE, Va., Oct. 25, 2023 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, recently hosted a virtual key opinion leader webinar. with addiction experts Joseph Volpicelli, M.D., Ph.D., Executive Director and Founder of the Volpicelli Center; and Jonathan Hunt-Glassman, MBA, Chief Executive Officer and Co-founder of Oar Health, to discuss alcohol use disorder (AUD), the current treatment landscape, and the need for non-abstinence-based therapeutics. Both experts are nationally recognized for their efforts in providing improved treatment options to patients with AUD.

To improve engagement in medical treatment, the key opinion leaders expressed the belief that barriers to treatment could be reduced by giving people additional options such as non-abstinence-based therapies. A non-abstinence-based treatment approach will provide patients with the power to choose more realistic goals of reducing alcohol consumption rather than abstinence. Reductions in excessive drinking, even without complete abstinence, can have a major public health impact on morbidity and mortality associated with AUD.

“In the AUD treatment community, there is a strong bias that abstinence is the only legitimate goal. However, the academic community has shown that non-abstinence-based approaches lead to very beneficial results,” said Dr. Volpicelli. “Reduction in heavy drinking is associated with improvements in day-to-day functioning, socialization with peers, physical function, and self-esteem. Recovery is more than abstinence. Recovery is about doing better in life.

RELATED NEWS: Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market 


According to the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and other published research:

  • AUD is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, and health consequences. 1
  • 28.6 million adults ages 18 and older had AUD in 2021. 2
  • An estimated 894,000 adolescents ages 12 to 17 had AUD in 2021. 2
  • Over 140,000 people die from alcohol-related causes annually, making alcohol the fourth-leading preventable cause of death in the United States. 1

READ FULL RELEASE HERE.


FOR MORE NEWS ON ADIAL, SUBSCRIBE.


INVESTOR PRESENTATION

VIEW VIDEO PRESENTATION


This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the need for non-abstinence-based options being paramount, non-abstinence-based treatment providing patients with the power to choose more realistic goals of reducing alcohol consumption rather than abstinence, the treatment having a major public health impact on morbidity and mortality associated with AUD, there being a shift away from the all-or-nothing approach currently applied to treating AUD as physicians’ understanding of addiction continues to grow and evolve, there will be a shift away from the all-or-nothing approach currently applied to treating AUD, physicians being more empowered to recommend a broader spectrum of treatments better tailored to meet patients’ needs and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to execute on our business strategy and bring AD04 to large markets in the most cost-effective and timely manner, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to retain our key employees or maintain our Nasdaq listing, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements and the continued maintenance and growth of our patent estate. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2022, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Contact:
Crescendo Communications, LLC                        
David Waldman / Alexandra Schilt                        
Tel: 212-671-1020                                
Email: [email protected]